Why isn’t a shipment fully cleared once it passes through customs?
When a shipment enters the United States, it is initially released to the importer on a conditional basis. This means that while the goods may be in the importer’s possession, the release is not final. Agencies like the FDA, which heavily regulate certain products, may still be evaluating the shipment. Customs uses a bonding process to allow the goods to be released conditionally. This conditional release becomes unconditional 30 days after both customs and the FDA have completed their evaluations, but even then, customs can revisit the entry for up to seven years to verify compliance with regulations such as duty payments and product classification.
What are CF-28 and CF-29 forms and how do they differ?
The CF-28 is a form issued when customs is investigating an entry to ensure compliance with regulations. It involves gathering more information on specific entries to confirm that the importer has the necessary documentation at the time of entry. The CF-29, however, is issued when customs has moved from inquiry to formal investigation. This phase carries the risk of penalties if violations are found. While a CF-28 allows for corrective measures such as prior disclosures or requests for advice, a CF-29 indicates that customs is seriously investigating potential violations.
What issues might trigger a post-entry audit by customs?
Post-entry audits can be triggered by several factors including valuation discrepancies, incorrect classification, and country of origin issues. Customs is particularly concerned with ensuring correct duty payments, accuracy in product classification, and compliance with any intellectual property laws. For FDA-regulated products, customs may also investigate compliance with additional health and safety standards. Any suspicion of misdeclaration or fraudulent activity can prompt an audit.
How far back can customs look when reviewing entries?
Customs has the authority to review entries for up to seven years after the initial entry. Importers are required to maintain records for this time period to comply with potential investigations. If issues are found, such as incorrect classification or duty payments, customs can impose penalties that are significantly higher than the original duty owed, depending on the severity and intent of the violation.
How does FDA-related information factor into post-entry reviews?
FDA-related information can be pivotal in post-entry reviews, especially if customs and the FDA are concerned about specific product types. For example, issues can arise if the actual country of origin differs from what was declared and would have resulted in an FDA import alert. In cases involving potential counterfeit or unapproved drugs, customs may collaborate with the FDA to address these concerns.
What systems should companies have to reduce the risk of post-entry audits?
Companies should implement robust systems to manage import documentation and ensure compliance with all regulatory requirements. This includes having detailed purchase orders that specify all regulatory requirements and maintaining thorough documentation to support all declarations made during entry. Regular audits of internal processes and collaboration with customs experts can help identify and address potential compliance issues before they result in post-entry audits.
If you’re facing challenges with importing FDA-regulated products, we’re here to help you navigate the process smoothly. Let us be your guide through the complexities of trade tariffs, FDA compliance, and border issues. Visit us at FDAImports or contact us directly at contact@fdaimports.com for assistance.
This news update is provided for informational and educational purposes only and does not constitute legal advice and is not intended to form an attorney-client relationship. Please contact your regular FDAImports representative for additional information.
